{"gene":"F8","run_date":"2026-06-09T23:54:43","timeline":{"discoveries":[{"year":1987,"finding":"FVIII inhibitor epitopes map to either the 92-kDa polypeptide (and its 54-kDa/44-kDa thrombin fragments) or the 80-kDa polypeptide (and its 72-kDa thrombin fragment), establishing that inhibitory antibodies target distinct FVIII polypeptide domains. Inhibitors are of restricted polyclonal origin containing IgG-1 and IgG-4 subclasses, with different IgG subclasses showing differential reactivity to specific FVIII polypeptides.","method":"Immunoblotting of purified FVIII with inhibitor plasmas; affinity purification and quantitative radial immunodiffusion; monoclonal antibodies specific for IgG subclasses","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct immunoblotting of purified protein, multiple inhibitor plasmas tested, single lab with two orthogonal methods","pmids":["2436689"],"is_preprint":false},{"year":2009,"finding":"Combined deficiency of FV and FVIII (F5F8D) is caused by mutations in LMAN1 or MCFD2, which encode components of an ER-to-Golgi cargo receptor complex. MCFD2 is a calcium-dependent EF-hand domain protein that forms a heteromeric complex with LMAN1; missense mutations in MCFD2 EF-hand domains abolish interaction with LMAN1. The B domain of FVIII is implicated in mediating its interaction with the LMAN1-MCFD2 complex.","method":"Genetic mapping of F5F8D mutations; biochemical characterization of LMAN1-MCFD2 complex; mutational analysis of MCFD2 EF-hand domains","journal":"British journal of haematology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — review synthesizing multiple experimental studies identifying the cargo receptor complex; replicated across labs but this paper is a review","pmids":["19183188"],"is_preprint":false},{"year":2011,"finding":"LMAN1-deficient mice show ~50% reduction in plasma FV and FVIII and platelet FV levels, confirming that the LMAN1-MCFD2 complex functions as an ER-to-Golgi cargo receptor for FV and FVIII. LMAN1 deficiency causes slight ER distension with accumulation of α1-antitrypsin and GRP78 in hepatocytes. LMAN1 deficiency had no effect on COPII-coated vesicle formation in vitro.","method":"LMAN1 knockout mouse analysis; plasma coagulation factor measurements; in vitro COPII vesicle formation assay; electron microscopy of hepatocytes; immunoblotting","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — genetic knockout model with direct measurement of cargo levels, in vitro vesicle assay, and ultrastructural analysis in a single rigorous study","pmids":["21795745"],"is_preprint":false},{"year":2006,"finding":"Regulated secretion of FVIII occurs only when there is endogenous synthesis of FVIII together with VWF in endothelial cells, demonstrating that co-synthesis with VWF is required for FVIII storage in regulated secretory pools (Weibel-Palade bodies) and stimulus-dependent release.","method":"DDAVP-stimulated release studies in endothelial cells; co-expression analysis of VWF and FVIII","journal":"Pediatric blood & cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional release assay with endogenous synthesis requirement demonstrated, single lab","pmids":["16470522"],"is_preprint":false},{"year":2018,"finding":"Stabilin-2 (encoded by STAB2) functions as a clearance and immunoregulatory receptor for the VWF-FVIII complex. Stabilin-2-expressing cells bind and internalize human VWF and FVIII in a VWF-dependent manner. Stabilin-2-deficient mice show prolonged human VWF-FVIII half-life. The stabilin-2 variant p.E2377K decreases stabilin-2 expression and impairs VWF endocytosis. Co-infusion of VWF-FVIII with stabilin-2 ligand hyaluronic acid attenuates the immune response to exogenous FVIII.","method":"Cell binding and internalization assays; stabilin-2 knockout mouse pharmacokinetic studies; heterologous expression of stabilin-2 variant; immunogenicity assays in STAB2-deficient mice","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (KO mouse PK, cell internalization, variant expression, immunogenicity) in a single rigorous study","pmids":["30124466"],"is_preprint":false},{"year":2013,"finding":"Mesenchymal stem cells (MSC) isolated from human lung, liver, brain, and bone marrow express FVIII mRNA and produce functional FVIII protein. In MSC, FVIII protein localizes to the perinuclear region rather than in granules, and functional FVIII is detectable in MSC supernatants and cell lysates.","method":"Quantitative RT-PCR; confocal immunofluorescence microscopy with FVIII-specific antibody; functional FVIII measurement by aPTT and chromogenic assays","journal":"Journal of cellular physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (RT-PCR, immunofluorescence, functional assay), single lab","pmids":["23042590"],"is_preprint":false},{"year":2008,"finding":"VWF reduces the immunogenicity of FVIII by inhibiting uptake of FVIII by immature dendritic cells and inhibiting activation of FVIII-specific T cells in a dose-dependent manner. Recombinant VWF lacking the FVIII-binding domain did not inhibit T-cell activation, demonstrating that VWF must bind FVIII to exert its immunomodulatory effect.","method":"In vitro dendritic cell FVIII uptake assays; T-cell activation assays with VWF and VWF mutant lacking FVIII-binding domain","journal":"Thrombosis research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro functional assays with domain-deletion control, single lab review summarizing experimental findings","pmids":["18549909"],"is_preprint":false},{"year":2017,"finding":"The F8 missense mutation c.6046C>T/p.R2016W in exon 19 exerts pleiotropic effects: it impairs both FVIII secretion (antigen ~11% of wild-type) and activity (~6% of wild-type) and decreases correct mRNA splicing to 70%. Antisense U7snRNA masking the mutated exon 19 region confirmed the presence of a splicing regulatory element. Additional clustered missense mutations (p.G2013R, p.E2018G, p.N2038S) also reduce exon inclusion, demonstrating that the amino acid and splicing codes overlap in this region.","method":"Lentiviral vector expression studies; minigene splicing assays; ectopic F8 mRNA analysis from patient samples; antisense U7snRNA rescue experiments; FVIII antigen and activity measurements","journal":"Haematologica","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — multiple orthogonal methods (patient mRNA, minigene, recombinant expression, antisense rescue) in a single study with mechanistic dissection","pmids":["29170251"],"is_preprint":false},{"year":2021,"finding":"Extensive characterization of 30 F8 exon 19 variants revealed pleiotropic effects on both mRNA splicing and protein biology. A single engineered U1snRNA rescued aberrant mRNA splicing of nine different F8 variants. A chaperone-like drug improved FVIII protein secretion for four missense variants impairing protein folding, establishing that protein folding and secretion are separable from splicing as pathogenic mechanisms.","method":"Recombinant expression assays; minigene splicing assays; in silico prediction algorithms; engineered U1snRNA rescue; chaperone drug treatment; FVIII antigen and activity measurement","journal":"American journal of human genetics","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — multiple orthogonal methods across 30 variants with functional rescue experiments in a single rigorous study","pmids":["34242570"],"is_preprint":false},{"year":2010,"finding":"A point mutation (Leu176Pro) in the A1 domain of rat FVIII causes hemophilia A by disrupting the tertiary structure of the FVIII molecule. The F8 gene has an autosomal location on chromosome 18 in rats (versus X-linked in mice and humans). Administration of human recombinant FVIII corrects the coagulation abnormality in affected rats.","method":"F8 cDNA sequencing to identify causative mutation; coagulation factor activity assays; FVIII replacement correction experiment","journal":"Journal of thrombosis and haemostasis","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mutation identification with functional correction assay, single lab, animal model","pmids":["20626616"],"is_preprint":false},{"year":2019,"finding":"The native F8 promoter drives FVIII expression predominantly in liver sinusoidal endothelial cells, with some expression in hematopoietic organs, as demonstrated by GFP reporter under pF8 in mice. Depletion of regulatory T cells (Tregs) in lentiviral-treated mice allowed formation of anti-FVIII antibodies, indicating that Tregs mediate immune tolerance to FVIII under pF8-driven gene therapy.","method":"Lentiviral vector with GFP reporter under native F8 promoter; in vivo GFP expression analysis; FVIII activity measurement; Treg depletion experiments in hemophilic mice","journal":"Blood advances","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct in vivo reporter assay for promoter activity, functional Treg depletion experiment, single lab","pmids":["30862611"],"is_preprint":false},{"year":2022,"finding":"In human lymphatic endothelial cells (hLECs) where FVIII is significantly expressed, FVIII and VWF co-localize in Weibel-Palade bodies (WPBs) and are released together upon stimulation. A reciprocal relationship between FVIII and VWF expression levels exists across endothelial cell types. Exposure to laminar shear stress markedly reduces both FVIII and VWF expression in hLECs.","method":"Immunofluorescence microscopy; stimulated release assays; shear stress exposure; RNA and protein quantification across multiple endothelial cell types","journal":"Journal of thrombosis and haemostasis","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct co-localization by immunofluorescence with stimulated release assay, multiple cell types compared, single lab","pmids":["35950488"],"is_preprint":false},{"year":2023,"finding":"In ER-to-Golgi trafficking of FV and FVIII, MCFD2 is the primary cargo-binding component while LMAN1 serves mainly as a shuttling carrier of MCFD2. LMAN1 with mutations abolishing carbohydrate binding can still partially rescue FV/FVIII secretion, indicating N-glycan binding is not essential for FV/FVIII transport. Overexpression of either wild-type or mutant MCFD2 alone is sufficient to rescue FV/FVIII secretion in LMAN1-deficient cells.","method":"LMAN1- and MCFD2-deficient cell lines (HEK293T, HepG2, HCT116); FV/FVIII secretion assays; rescue experiments with LMAN1 carbohydrate-binding mutants and MCFD2 overexpression","journal":"Blood advances","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — multiple cell-type KO lines, mutagenesis of carbohydrate-binding domain, and rescue experiments with orthogonal approaches in a single study","pmids":["36490287"],"is_preprint":false},{"year":2022,"finding":"Immune tolerance to FVIII under non-hemophilic conditions is maintained by PD-L1-expressing regulatory T cells (Tregs) that ligate PD-1 on FVIII-specific B cells, causing B cell apoptosis. FVIII-deficient mice lack these Tregs and develop inhibitors. Repetitive FVIII injection in an ITI mouse model induces FVIII-specific PD-L1+ Tregs that re-engage removal of inhibitor-forming B cells. FVIII-specific Tregs upregulate PD-L1 in hemophilia patients after successful ITI.","method":"FVIII-deficient mouse model; ITI mouse model with repetitive FVIII injection; Treg characterization by flow cytometry; PD-1/PD-L1 blocking experiments; B cell apoptosis assays; human patient samples post-ITI","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 / Strong — mechanistic dissection in mouse models and human patients, multiple orthogonal methods (flow cytometry, apoptosis assays, blocking experiments), replicated across species","pmids":["36107620"],"is_preprint":false},{"year":2019,"finding":"MicroRNAs miR-374b-5p and miR-30c-5p suppress FVIII expression by targeting the 3' UTR of F8 mRNA. Overexpression of miR-374b or miR-30c decreased FVIII expression in cell lines that constitutively express FVIII, while an miR-30c inhibitor partially restored FVIII expression.","method":"miRNA sequencing from hemophilia A patients without F8 coding mutations; overexpression of specific miRNAs in FVIII-expressing cell lines; miRNA inhibitor rescue experiment; FVIII expression measurement","journal":"Transfusion","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct functional assay with miRNA overexpression and inhibitor rescue in FVIII-expressing cell lines, single lab, two miRNAs tested","pmids":["31785023"],"is_preprint":false},{"year":2021,"finding":"A 23.4-kb tandem duplication of the proximal F8 gene (promoter, exon 1, and part of intron 1) causes twofold or greater upregulation of F8 mRNA and extremely elevated FVIII levels (>400%), resulting in severe thrombophilia. A 927-bp region within F8 intron 1 showed >45-fold increased reporter activity in endothelial cells in a luciferase assay, identifying it as a transcriptional enhancer element for F8.","method":"Genetic analysis of thrombophilic families; RNA quantification; luciferase reporter assay of intron 1 sequences in endothelial cells; chromatin accessibility (open chromatin signatures) analysis","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — luciferase reporter assay identifying functional enhancer, cosegregation in two families, RNA quantification; single lab","pmids":["33275657"],"is_preprint":false},{"year":2019,"finding":"CRISPR/Cas9-mediated homology-directed repair can insert a functional B-domain-deleted FVIII gene at the FVIII locus in hemophilia A patient-derived iPSCs at high frequency (81.81%). Endothelial cells differentiated from gene-corrected iPSCs produce functionally active FVIII protein, demonstrating that the FVIII locus is a suitable site for integration and endothelial expression of corrected FVIII.","method":"CRISPR/Cas9 HDR gene targeting in patient iPSCs; iPSC differentiation to endothelial cells; FVIII functional activity assay","journal":"Experimental & molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genome editing with functional validation in differentiated cells, single lab","pmids":["30996250"],"is_preprint":false},{"year":2018,"finding":"The FVIII peptide FVIII2194-2213 contains an immunodominant HLA-DRA*01-DRB1*01:01-restricted T-cell epitope. The core binding residues are F2196, M2199, A2201, and S2204. The substitution F2196A abrogates T-cell clone proliferation to the wild-type sequence. B-domain-deleted FVIII proteins with F2196K or M2199A substitutions show reduced immunogenicity while retaining procoagulant activity comparable to wild-type.","method":"Peptide-MHC class II binding assays; T-cell proliferation assays with Ala-substituted peptides; recombinant BDD-FVIII protein expression and functional activity measurement; T-cell clone stimulation with recombinant FVIII-C2 domain proteins","journal":"Blood advances","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — multiple orthogonal methods (MHC binding, T-cell clones, recombinant protein activity, natural processing validation) in a single rigorous study","pmids":["29444872"],"is_preprint":false}],"current_model":"FVIII (F8) is a coagulation cofactor synthesized predominantly in liver sinusoidal endothelial cells and co-secreted with VWF from Weibel-Palade bodies; its ER-to-Golgi transport requires the LMAN1-MCFD2 cargo receptor complex in which MCFD2 directly binds FV/FVIII cargo while LMAN1 serves as a shuttling carrier, VWF protects FVIII from proteolytic degradation in plasma and reduces its immunogenicity by blocking antigen-presenting cell uptake, stabilin-2 on endothelial cells mediates clearance of the VWF-FVIII complex, immune tolerance to therapeutic FVIII is maintained by PD-L1+ regulatory T cells that drive apoptosis of FVIII-specific B cells via PD-1 ligation, and F8 gene expression is regulated by an intronic enhancer element in intron 1 and fine-tuned post-transcriptionally by miRNAs targeting the 3' UTR."},"narrative":{"mechanistic_narrative":"F8 encodes coagulation factor VIII (FVIII), a plasma procoagulant cofactor whose biology spans biosynthesis, intracellular trafficking, chaperoned secretion, plasma stabilization, clearance, and immune recognition [PMID:21795745, PMID:30124466]. Newly synthesized FVIII exits the ER via the LMAN1-MCFD2 cargo receptor complex, in which MCFD2 is the primary cargo-binding component and LMAN1 acts as a shuttling carrier; loss of this complex causes combined FV/FVIII deficiency and roughly halves plasma FVIII, while N-glycan binding by LMAN1 is dispensable for transport [PMID:19183188, PMID:21795745, PMID:36490287]. FVIII is expressed predominantly in liver sinusoidal endothelial cells and in lymphatic endothelium, where co-synthesis with VWF directs it into Weibel-Palade bodies for stimulus-dependent regulated secretion [PMID:30862611, PMID:35950488, PMID:16470522]. In plasma, VWF binding shields FVIII and limits its immunogenicity by blocking uptake by dendritic cells and downstream T-cell activation, and the VWF-FVIII complex is cleared through the endothelial scavenger receptor stabilin-2 [PMID:18549909, PMID:30124466]. Immune tolerance to FVIII is enforced by PD-L1+ regulatory T cells that ligate PD-1 on FVIII-specific B cells to drive their apoptosis; inhibitory antibodies that arise target distinct epitopes on the 92-kDa and 80-kDa FVIII polypeptides and an immunodominant HLA-DR-restricted T-cell epitope in the C2 region (residues 2194-2213) [PMID:36107620, PMID:2436689, PMID:29444872]. F8 output is set transcriptionally by an intron 1 enhancer active in endothelial cells and post-transcriptionally by 3'UTR-targeting miRNAs, and pathogenic exon 19 variants act pleiotropically by simultaneously disrupting mRNA splicing and protein folding/secretion [PMID:33275657, PMID:31785023, PMID:29170251, PMID:34242570].","teleology":[{"year":1987,"claim":"Defined the molecular targets of pathogenic FVIII inhibitors, establishing that inhibitory antibodies recognize distinct FVIII polypeptide domains rather than a single site.","evidence":"Immunoblotting of purified FVIII against inhibitor plasmas with IgG subclass-specific monoclonals","pmids":["2436689"],"confidence":"Medium","gaps":["Did not map epitopes to specific residues or domains structurally","Did not link epitope specificity to clinical inhibitor titer or persistence"]},{"year":2006,"claim":"Showed that regulated, stimulus-dependent FVIII secretion requires endogenous co-synthesis with VWF, explaining how FVIII enters Weibel-Palade body storage pools.","evidence":"DDAVP-stimulated release and VWF/FVIII co-expression studies in endothelial cells","pmids":["16470522"],"confidence":"Medium","gaps":["Did not define the in vivo endothelial cell type responsible","Trafficking determinants on FVIII directing WPB storage not mapped"]},{"year":2008,"claim":"Established a mechanistic basis for VWF's immunoprotective effect by showing VWF must bind FVIII to block dendritic-cell uptake and T-cell activation.","evidence":"In vitro DC uptake and T-cell activation assays using VWF and a FVIII-binding-deficient VWF mutant","pmids":["18549909"],"confidence":"Medium","gaps":["In vitro only; no in vivo immunogenicity confirmation","Receptor mediating DC uptake of free FVIII not identified"]},{"year":2009,"claim":"Identified the LMAN1-MCFD2 cargo receptor as the cause of combined FV/FVIII deficiency, defining a dedicated ER-to-Golgi export pathway for FVIII.","evidence":"Genetic mapping of F5F8D mutations and biochemical/mutational analysis of MCFD2 EF-hand domains (review)","pmids":["19183188"],"confidence":"Medium","gaps":["Review synthesis rather than primary data","Precise FVIII B-domain determinants contacting the receptor not resolved"]},{"year":2010,"claim":"Demonstrated in a rat model that a single A1-domain point mutation causes hemophilia A via tertiary structure disruption, correctable by FVIII replacement.","evidence":"F8 cDNA sequencing, coagulation activity assays, and recombinant FVIII correction in affected rats","pmids":["20626616"],"confidence":"Medium","gaps":["Structural disruption inferred, not directly visualized","Rat F8 is autosomal, limiting direct comparison to human X-linked locus"]},{"year":2011,"claim":"Provided in vivo genetic proof that LMAN1 functions as a FV/FVIII cargo receptor, with deficiency halving plasma factor levels without disrupting COPII vesicle formation.","evidence":"LMAN1-knockout mouse coagulation measurements, in vitro COPII assay, and hepatocyte EM","pmids":["21795745"],"confidence":"High","gaps":["Residual ~50% secretion implies an LMAN1-independent export route","Did not separate LMAN1 from MCFD2 contributions"]},{"year":2013,"claim":"Revealed that mesenchymal stem cells from multiple tissues can express and secrete functional FVIII, broadening the cellular sources of FVIII beyond endothelium.","evidence":"RT-PCR, confocal immunofluorescence, and aPTT/chromogenic functional FVIII assays in MSCs","pmids":["23042590"],"confidence":"Medium","gaps":["Physiological contribution of MSC-derived FVIII to plasma levels unknown","Perinuclear (non-granular) localization mechanism not explained"]},{"year":2017,"claim":"Showed that an exon 19 missense mutation is pleiotropic, simultaneously impairing splicing and protein secretion/activity, establishing overlap of the amino-acid and splicing codes in F8.","evidence":"Patient mRNA analysis, minigene splicing assays, lentiviral expression, and antisense U7snRNA rescue","pmids":["29170251"],"confidence":"High","gaps":["Single variant focus; generality across the gene not yet shown","Therapeutic feasibility of antisense correction in vivo untested"]},{"year":2018,"claim":"Identified stabilin-2 as a clearance and immunoregulatory receptor for the VWF-FVIII complex, linking plasma half-life to endothelial scavenging.","evidence":"Cell internalization assays, STAB2-knockout mouse pharmacokinetics, variant expression, and immunogenicity assays","pmids":["30124466"],"confidence":"High","gaps":["Relative contribution of stabilin-2 versus other clearance receptors not quantified","Mechanism linking clearance to reduced immunogenicity incompletely defined"]},{"year":2018,"claim":"Mapped an immunodominant HLA-DR-restricted T-cell epitope in the C2 region and showed engineered substitutions reduce immunogenicity while preserving procoagulant activity.","evidence":"Peptide-MHC binding, T-cell clone proliferation with Ala-scan peptides, and recombinant BDD-FVIII activity assays","pmids":["29444872"],"confidence":"High","gaps":["Single epitope; full T-cell epitope repertoire not enumerated","Reduced-immunogenicity variants not validated in vivo for tolerance"]},{"year":2019,"claim":"Defined transcriptional control of F8 by localizing expression to liver sinusoidal endothelial cells under the native promoter and showed Tregs mediate tolerance to FVIII.","evidence":"GFP reporter under native F8 promoter in mice plus Treg depletion in hemophilic mice","pmids":["30862611"],"confidence":"Medium","gaps":["Treg subset identity left to later work","Promoter elements driving LSEC specificity not dissected"]},{"year":2019,"claim":"Established post-transcriptional regulation of F8 by identifying 3'UTR-targeting miRNAs that suppress FVIII expression.","evidence":"Patient miRNA sequencing plus miRNA overexpression and inhibitor rescue in FVIII-expressing cell lines","pmids":["31785023"],"confidence":"Medium","gaps":["Only two miRNAs tested; in vivo relevance to plasma FVIII unproven","Endogenous regulatory contexts driving these miRNAs unknown"]},{"year":2019,"claim":"Demonstrated that the FVIII locus itself is a viable site for HDR-based gene correction with functional endothelial FVIII output.","evidence":"CRISPR/Cas9 HDR insertion of B-domain-deleted FVIII in patient iPSCs and differentiation to FVIII-producing endothelial cells","pmids":["30996250"],"confidence":"Medium","gaps":["In vivo engraftment and durable correction not tested","Off-target and integration safety not assessed"]},{"year":2021,"claim":"Identified an intron 1 transcriptional enhancer whose duplication drives F8 overexpression and thrombophilia, defining a cis-regulatory determinant of FVIII levels.","evidence":"Thrombophilic family genetics, RNA quantification, endothelial luciferase reporter assays, and chromatin accessibility analysis","pmids":["33275657"],"confidence":"Medium","gaps":["Trans-acting factors binding the enhancer not identified","Cosegregation limited to two families"]},{"year":2021,"claim":"Generalized the pleiotropy of exon 19 variants across 30 alleles and separated splicing defects from folding/secretion defects using distinct RNA- and protein-targeted rescues.","evidence":"Recombinant expression, minigene assays, engineered U1snRNA splicing rescue, and chaperone-drug secretion rescue across 30 variants","pmids":["34242570"],"confidence":"High","gaps":["Rescue approaches validated in cell models only","Variant-specific mechanism assignment may not extend to other exons"]},{"year":2022,"claim":"Extended the cellular map of FVIII to lymphatic endothelium, showing FVIII/VWF co-localization in WPBs, a reciprocal expression relationship, and shear-stress downregulation.","evidence":"Immunofluorescence, stimulated release assays, and shear-stress exposure across endothelial cell types","pmids":["35950488"],"confidence":"Medium","gaps":["Physiological contribution of lymphatic endothelium to plasma FVIII unclear","Mechanism of reciprocal FVIII/VWF regulation undefined"]},{"year":2022,"claim":"Defined a mechanism of natural and acquired tolerance to FVIII via PD-L1+ Tregs that drive PD-1-mediated apoptosis of FVIII-specific B cells, linking tolerance to inhibitor prevention and ITI success.","evidence":"FVIII-deficient and ITI mouse models, Treg flow cytometry, PD-1/PD-L1 blockade, B-cell apoptosis assays, and post-ITI human samples","pmids":["36107620"],"confidence":"High","gaps":["Antigen-specific Treg induction triggers incompletely defined","Translation to predictive clinical biomarkers not established"]},{"year":2023,"claim":"Resolved the division of labor within the FVIII export receptor, showing MCFD2 is the cargo-binding component while LMAN1 acts as its shuttling carrier and N-glycan binding is dispensable.","evidence":"LMAN1- and MCFD2-deficient HEK293T/HepG2/HCT116 lines with carbohydrate-binding mutant and MCFD2-overexpression rescue assays","pmids":["36490287"],"confidence":"High","gaps":["Structural basis of MCFD2-FVIII cargo recognition not defined","Identity of the residual LMAN1-independent secretion route unknown"]},{"year":null,"claim":"How transcriptional (intron 1 enhancer), post-transcriptional (miRNA), trafficking (LMAN1-MCFD2), and immune-tolerance (PD-L1+ Treg) layers are integrated to set physiological FVIII levels in vivo remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified in vivo model coupling FVIII output, clearance, and tolerance","Trans-acting regulators of the F8 enhancer and miRNAs unidentified","Structural mechanism of cargo recognition and inhibitor epitope architecture incomplete"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[2,10]}],"localization":[{"term_id":"GO:0031410","term_label":"cytoplasmic vesicle","supporting_discovery_ids":[3,11]},{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[2,12]},{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[4,6]}],"pathway":[{"term_id":"R-HSA-109582","term_label":"Hemostasis","supporting_discovery_ids":[2,10]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[13,17,4]},{"term_id":"R-HSA-9609507","term_label":"Protein localization","supporting_discovery_ids":[2,12]}],"complexes":["Weibel-Palade body VWF-FVIII complex"],"partners":["VWF","LMAN1","MCFD2","STAB2"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P00451","full_name":"Coagulation factor VIII","aliases":["Antihemophilic factor","AHF","Procoagulant component"],"length_aa":2351,"mass_kda":267.0,"function":"Factor VIII, along with calcium and phospholipid, acts as a cofactor for F9/factor IXa when it converts F10/factor X to the activated form, factor Xa","subcellular_location":"Secreted, extracellular space","url":"https://www.uniprot.org/uniprotkb/P00451/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/F8","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/F8","total_profiled":1310},"omim":[{"mim_id":"621535","title":"SPINOCEREBELLAR ATAXIA 52; SCA52","url":"https://www.omim.org/entry/621535"},{"mim_id":"621143","title":"HOLOPROSENCEPHALY 10; HPE10","url":"https://www.omim.org/entry/621143"},{"mim_id":"620865","title":"EHLERS-DANLOS SYNDROME, CLASSIC-LIKE, 3; EDSCLL3","url":"https://www.omim.org/entry/620865"},{"mim_id":"620152","title":"HYPOMAGNESEMIA 7, RENAL, WITH OR WITHOUT DILATED CARDIOMYOPATHY; HOMG7","url":"https://www.omim.org/entry/620152"},{"mim_id":"618879","title":"NEURODEVELOPMENTAL DISORDER WITH HYPOTONIA AND CEREBELLAR ATROPHY, WITH OR WITHOUT SEIZURES; NEDHCAS","url":"https://www.omim.org/entry/618879"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"heart muscle","ntpm":51.1}],"url":"https://www.proteinatlas.org/search/F8"},"hgnc":{"alias_symbol":["FVIII","DXS1253E","HEMA"],"prev_symbol":["F8C"]},"alphafold":{"accession":"P00451","domains":[{"cath_id":"2.60.40.420","chopping":"17-39_64-228_250-347","consensus_level":"medium","plddt":88.6512,"start":17,"end":347},{"cath_id":"2.60.40.420","chopping":"401-729","consensus_level":"high","plddt":87.1629,"start":401,"end":729},{"cath_id":"2.60.40.420","chopping":"1715-1734_1748-2034","consensus_level":"high","plddt":87.6309,"start":1715,"end":2034},{"cath_id":"2.60.120.260","chopping":"2041-2193","consensus_level":"medium","plddt":91.013,"start":2041,"end":2193},{"cath_id":"2.60.120.260","chopping":"2194-2351","consensus_level":"medium","plddt":90.4669,"start":2194,"end":2351}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P00451","model_url":"https://alphafold.ebi.ac.uk/files/AF-P00451-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P00451-F1-predicted_aligned_error_v6.png","plddt_mean":60.75},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=F8","jax_strain_url":"https://www.jax.org/strain/search?query=F8"},"sequence":{"accession":"P00451","fasta_url":"https://rest.uniprot.org/uniprotkb/P00451.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P00451/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P00451"}},"corpus_meta":[{"pmid":"2436689","id":"PMC_2436689","title":"FVIII inhibitor IgG subclass and FVIII polypeptide specificity determined by immunoblotting.","date":"1987","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/2436689","citation_count":155,"is_preprint":false},{"pmid":"28064157","id":"PMC_28064157","title":"FVIII-specific human chimeric antigen receptor T-regulatory cells suppress T- and B-cell responses to FVIII.","date":"2016","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/28064157","citation_count":132,"is_preprint":false},{"pmid":"22103590","id":"PMC_22103590","title":"F8 and F9 mutations in US haemophilia patients: correlation with history of inhibitor and race/ethnicity.","date":"2011","source":"Haemophilia : the official journal of the World Federation of Hemophilia","url":"https://pubmed.ncbi.nlm.nih.gov/22103590","citation_count":111,"is_preprint":false},{"pmid":"16890983","id":"PMC_16890983","title":"Inhibition of TEGDMA and HEMA-induced genotoxicity and cell cycle arrest by N-acetylcysteine.","date":"2006","source":"Dental materials : official publication of the Academy of Dental Materials","url":"https://pubmed.ncbi.nlm.nih.gov/16890983","citation_count":101,"is_preprint":false},{"pmid":"9973348","id":"PMC_9973348","title":"Conditional stability of the HemA protein (glutamyl-tRNA reductase) regulates heme biosynthesis in Salmonella typhimurium.","date":"1999","source":"Journal of bacteriology","url":"https://pubmed.ncbi.nlm.nih.gov/9973348","citation_count":87,"is_preprint":false},{"pmid":"2544564","id":"PMC_2544564","title":"Cloning, genetic characterization, and nucleotide sequence of the hemA-prfA operon of Salmonella typhimurium.","date":"1989","source":"Journal of bacteriology","url":"https://pubmed.ncbi.nlm.nih.gov/2544564","citation_count":85,"is_preprint":false},{"pmid":"24355064","id":"PMC_24355064","title":"HEMA-induced cytotoxicity: oxidative stress, genotoxicity and apoptosis.","date":"2014","source":"International endodontic journal","url":"https://pubmed.ncbi.nlm.nih.gov/24355064","citation_count":73,"is_preprint":false},{"pmid":"30124466","id":"PMC_30124466","title":"The endothelial cell receptor stabilin-2 regulates VWF-FVIII complex half-life and immunogenicity.","date":"2018","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/30124466","citation_count":69,"is_preprint":false},{"pmid":"2548996","id":"PMC_2548996","title":"Isolation, nucleotide sequence, and preliminary characterization of the Escherichia coli K-12 hemA gene.","date":"1989","source":"Journal of bacteriology","url":"https://pubmed.ncbi.nlm.nih.gov/2548996","citation_count":69,"is_preprint":false},{"pmid":"2110138","id":"PMC_2110138","title":"Cloning and characterization of the hemA region of the Bacillus subtilis chromosome.","date":"1990","source":"Journal of bacteriology","url":"https://pubmed.ncbi.nlm.nih.gov/2110138","citation_count":59,"is_preprint":false},{"pmid":"18634839","id":"PMC_18634839","title":"Gene transfer to hemophilia A mice via oral delivery of FVIII-chitosan nanoparticles.","date":"2008","source":"Journal of controlled release : official journal of the Controlled Release Society","url":"https://pubmed.ncbi.nlm.nih.gov/18634839","citation_count":55,"is_preprint":false},{"pmid":"25582282","id":"PMC_25582282","title":"Parameters influencing FVIII pharmacokinetics in patients with severe and moderate haemophilia A.","date":"2015","source":"Haemophilia : the official journal of the World Federation of Hemophilia","url":"https://pubmed.ncbi.nlm.nih.gov/25582282","citation_count":55,"is_preprint":false},{"pmid":"14693206","id":"PMC_14693206","title":"Antioxidative vitamins decrease cytotoxicity of HEMA and TEGDMA in cultured cell lines.","date":"2004","source":"Archives of oral biology","url":"https://pubmed.ncbi.nlm.nih.gov/14693206","citation_count":54,"is_preprint":false},{"pmid":"30232086","id":"PMC_30232086","title":"Engineered FVIII-expressing cytotoxic T cells target and kill FVIII-specific B cells in vitro and in vivo.","date":"2018","source":"Blood advances","url":"https://pubmed.ncbi.nlm.nih.gov/30232086","citation_count":53,"is_preprint":false},{"pmid":"19183188","id":"PMC_19183188","title":"Recent developments in the understanding of the combined deficiency of FV and FVIII.","date":"2009","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/19183188","citation_count":48,"is_preprint":false},{"pmid":"24517184","id":"PMC_24517184","title":"Diagnosis and management challenges in patients with mild haemophilia A and discrepant FVIII measurements.","date":"2014","source":"Haemophilia : the official journal of the World Federation of Hemophilia","url":"https://pubmed.ncbi.nlm.nih.gov/24517184","citation_count":45,"is_preprint":false},{"pmid":"21795745","id":"PMC_21795745","title":"Mice deficient in LMAN1 exhibit FV and FVIII deficiencies and liver accumulation of α1-antitrypsin.","date":"2011","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/21795745","citation_count":44,"is_preprint":false},{"pmid":"2664455","id":"PMC_2664455","title":"Isolation and nucleotide sequence of the hemA gene of Escherichia coli K12.","date":"1989","source":"Molecular & general genetics : MGG","url":"https://pubmed.ncbi.nlm.nih.gov/2664455","citation_count":44,"is_preprint":false},{"pmid":"19148784","id":"PMC_19148784","title":"Immune response to FVIII in hemophilia A: an overview of risk factors.","date":"2009","source":"Clinical reviews in allergy & immunology","url":"https://pubmed.ncbi.nlm.nih.gov/19148784","citation_count":42,"is_preprint":false},{"pmid":"17486417","id":"PMC_17486417","title":"Effects of HEMA on type I collagen protein in human gingival fibroblasts.","date":"2007","source":"Cell biology and toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/17486417","citation_count":42,"is_preprint":false},{"pmid":"19141160","id":"PMC_19141160","title":"Combined FV and FVIII deficiency.","date":"2008","source":"Haemophilia : the official journal of the World Federation of Hemophilia","url":"https://pubmed.ncbi.nlm.nih.gov/19141160","citation_count":41,"is_preprint":false},{"pmid":"28490568","id":"PMC_28490568","title":"Noninvasive detection of F8 int22h-related inversions and sequence variants in maternal plasma of hemophilia carriers.","date":"2017","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/28490568","citation_count":41,"is_preprint":false},{"pmid":"17920114","id":"PMC_17920114","title":"HEMA reduces cell proliferation and induces apoptosis in vitro.","date":"2007","source":"Dental materials : official publication of the Academy of Dental Materials","url":"https://pubmed.ncbi.nlm.nih.gov/17920114","citation_count":40,"is_preprint":false},{"pmid":"8104869","id":"PMC_8104869","title":"G6PD haplotypes spanning Xq28 from F8C to red/green color vision.","date":"1993","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/8104869","citation_count":40,"is_preprint":false},{"pmid":"16470522","id":"PMC_16470522","title":"Regulated release of VWF and FVIII and the biologic implications.","date":"2006","source":"Pediatric blood & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/16470522","citation_count":39,"is_preprint":false},{"pmid":"22958194","id":"PMC_22958194","title":"F8 haplotype and inhibitor risk: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort.","date":"2012","source":"Haemophilia : the official journal of the World Federation of Hemophilia","url":"https://pubmed.ncbi.nlm.nih.gov/22958194","citation_count":39,"is_preprint":false},{"pmid":"31159172","id":"PMC_31159172","title":"Synthesis and Characterization of Silicone Contact Lenses Based on TRIS-DMA-NVP-HEMA Hydrogels.","date":"2019","source":"Polymers","url":"https://pubmed.ncbi.nlm.nih.gov/31159172","citation_count":39,"is_preprint":false},{"pmid":"12325022","id":"PMC_12325022","title":"High throughput mutation screening of the factor VIII gene (F8C) in hemophilia A: 37 novel mutations and genotype-phenotype correlation.","date":"2002","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/12325022","citation_count":37,"is_preprint":false},{"pmid":"21640196","id":"PMC_21640196","title":"DNA-damage, cell-cycle arrest and apoptosis induced in BEAS-2B cells by 2-hydroxyethyl methacrylate (HEMA).","date":"2011","source":"Mutation research","url":"https://pubmed.ncbi.nlm.nih.gov/21640196","citation_count":37,"is_preprint":false},{"pmid":"21091850","id":"PMC_21091850","title":"Immunoglobulin isotypes and functional anti-FVIII antibodies in response to FVIII treatment in Balb/c and C57BL/6 haemophilia A mice.","date":"2010","source":"Haemophilia : the official journal of the World Federation of Hemophilia","url":"https://pubmed.ncbi.nlm.nih.gov/21091850","citation_count":35,"is_preprint":false},{"pmid":"16182358","id":"PMC_16182358","title":"Adhesive resin and the hydrophilic monomer HEMA induce VEGF expression on dental pulp cells and macrophages.","date":"2005","source":"Dental materials : official publication of the Academy of Dental Materials","url":"https://pubmed.ncbi.nlm.nih.gov/16182358","citation_count":35,"is_preprint":false},{"pmid":"20551083","id":"PMC_20551083","title":"Expression, engineering and characterization of the tumor-targeting heterodimeric immunocytokine F8-IL12.","date":"2010","source":"Protein engineering, design & selection : PEDS","url":"https://pubmed.ncbi.nlm.nih.gov/20551083","citation_count":34,"is_preprint":false},{"pmid":"33545871","id":"PMC_33545871","title":"Electrospun GelMA fibers and p(HEMA) matrix composite for corneal tissue engineering.","date":"2020","source":"Materials science & engineering. C, Materials for biological applications","url":"https://pubmed.ncbi.nlm.nih.gov/33545871","citation_count":34,"is_preprint":false},{"pmid":"11857744","id":"PMC_11857744","title":"The identification and classification of 41 novel mutations in the factor VIII gene (F8C).","date":"2002","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/11857744","citation_count":32,"is_preprint":false},{"pmid":"31811387","id":"PMC_31811387","title":"Cell Loaded GelMA:HEMA IPN hydrogels for corneal stroma engineering.","date":"2019","source":"Journal of materials science. Materials in medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31811387","citation_count":32,"is_preprint":false},{"pmid":"3105317","id":"PMC_3105317","title":"Recombination between the factor VIII gene and the DXS52 locus gives the most probable genetic order as centromere-fra(X)-DXS15-DXS52-F8C-telomere.","date":"1987","source":"American journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/3105317","citation_count":32,"is_preprint":false},{"pmid":"7883699","id":"PMC_7883699","title":"Regulation of the hemA gene during 5-aminolevulinic acid formation in Pseudomonas aeruginosa.","date":"1995","source":"Journal of bacteriology","url":"https://pubmed.ncbi.nlm.nih.gov/7883699","citation_count":31,"is_preprint":false},{"pmid":"2407729","id":"PMC_2407729","title":"Cloning and expression of a structural gene from Chlorobium vibrioforme that complements the hemA mutation in Escherichia coli.","date":"1990","source":"Journal of bacteriology","url":"https://pubmed.ncbi.nlm.nih.gov/2407729","citation_count":31,"is_preprint":false},{"pmid":"26025483","id":"PMC_26025483","title":"Assessment of HEMA and TEGDMA induced DNA damage by multiple genotoxicological endpoints in human lymphocytes.","date":"2015","source":"Dental materials : official publication of the Academy of Dental Materials","url":"https://pubmed.ncbi.nlm.nih.gov/26025483","citation_count":30,"is_preprint":false},{"pmid":"9222513","id":"PMC_9222513","title":"Selectivity of F8-actinomycin D for RNA:DNA hybrids and its anti-leukemia activity.","date":"1997","source":"Bioorganic & medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9222513","citation_count":29,"is_preprint":false},{"pmid":"30862611","id":"PMC_30862611","title":"FVIII expression by its native promoter sustains long-term correction avoiding immune response in hemophilic mice.","date":"2019","source":"Blood advances","url":"https://pubmed.ncbi.nlm.nih.gov/30862611","citation_count":29,"is_preprint":false},{"pmid":"29170251","id":"PMC_29170251","title":"Clustered F8 missense mutations cause hemophilia A by combined alteration of splicing and protein biosynthesis and activity.","date":"2017","source":"Haematologica","url":"https://pubmed.ncbi.nlm.nih.gov/29170251","citation_count":28,"is_preprint":false},{"pmid":"33275657","id":"PMC_33275657","title":"Partial F8 gene duplication (factor VIII Padua) associated with high factor VIII levels and familial thrombophilia.","date":"2021","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/33275657","citation_count":27,"is_preprint":false},{"pmid":"37874897","id":"PMC_37874897","title":"Thermoresponsive Smart Copolymer Coatings Based on P(NIPAM-co-HEMA) and P(OEGMA-co-HEMA) Brushes for Regenerative Medicine.","date":"2023","source":"ACS biomaterials science & engineering","url":"https://pubmed.ncbi.nlm.nih.gov/37874897","citation_count":26,"is_preprint":false},{"pmid":"18755506","id":"PMC_18755506","title":"Effects of TEGDMA and HEMA on the expression of COX-2 and iNOS in cultured murine macrophage cells.","date":"2008","source":"Dental materials : official publication of the Academy of Dental Materials","url":"https://pubmed.ncbi.nlm.nih.gov/18755506","citation_count":25,"is_preprint":false},{"pmid":"23042590","id":"PMC_23042590","title":"Mesenchymal stem cells contribute to endogenous FVIII:c production.","date":"2013","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/23042590","citation_count":25,"is_preprint":false},{"pmid":"24729686","id":"PMC_24729686","title":"Fc-fusion technology and recombinant FVIII and FIX in the management of the hemophilias.","date":"2014","source":"Drug design, development and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/24729686","citation_count":24,"is_preprint":false},{"pmid":"32670285","id":"PMC_32670285","title":"B Cell Depletion Eliminates FVIII Memory B Cells and Enhances AAV8-coF8 Immune Tolerance Induction When Combined With Rapamycin.","date":"2020","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/32670285","citation_count":24,"is_preprint":false},{"pmid":"29444872","id":"PMC_29444872","title":"FVIII proteins with a modified immunodominant T-cell epitope exhibit reduced immunogenicity and normal FVIII activity.","date":"2018","source":"Blood advances","url":"https://pubmed.ncbi.nlm.nih.gov/29444872","citation_count":24,"is_preprint":false},{"pmid":"31785023","id":"PMC_31785023","title":"Clinical manifestation of hemophilia A in the absence of mutations in the F8 gene that encodes FVIII: role of microRNAs.","date":"2019","source":"Transfusion","url":"https://pubmed.ncbi.nlm.nih.gov/31785023","citation_count":24,"is_preprint":false},{"pmid":"23551875","id":"PMC_23551875","title":"Characterization of large deletions in the F8 gene using multiple competitive amplification and the genome walking technique.","date":"2013","source":"Journal of thrombosis and haemostasis : JTH","url":"https://pubmed.ncbi.nlm.nih.gov/23551875","citation_count":24,"is_preprint":false},{"pmid":"32351497","id":"PMC_32351497","title":"The Immune Response to the fVIII Gene Therapy in Preclinical Models.","date":"2020","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/32351497","citation_count":23,"is_preprint":false},{"pmid":"30996250","id":"PMC_30996250","title":"Restoration of FVIII expression by targeted gene insertion in the FVIII locus in hemophilia A patient-derived iPSCs.","date":"2019","source":"Experimental & molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30996250","citation_count":23,"is_preprint":false},{"pmid":"1793335","id":"PMC_1793335","title":"Structure and expression of the Chlorobium vibrioforme hemA gene.","date":"1991","source":"Archives of microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/1793335","citation_count":23,"is_preprint":false},{"pmid":"31461952","id":"PMC_31461952","title":"Solvent and HEMA Increase Adhesive Toxicity and Cytokine Release from Dental Pulp Cells.","date":"2019","source":"Materials (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/31461952","citation_count":22,"is_preprint":false},{"pmid":"8997718","id":"PMC_8997718","title":"Expression of the heme biosynthetic pathway genes hemCD, hemH, hemM, and hemA of Escherichia coli.","date":"1997","source":"FEMS microbiology letters","url":"https://pubmed.ncbi.nlm.nih.gov/8997718","citation_count":22,"is_preprint":false},{"pmid":"37285902","id":"PMC_37285902","title":"Comprehensive Analysis of Hemophilia A (CAHEA): Towards Full Characterization of the F8 Gene Variants by Long-Read Sequencing.","date":"2023","source":"Thrombosis and haemostasis","url":"https://pubmed.ncbi.nlm.nih.gov/37285902","citation_count":22,"is_preprint":false},{"pmid":"25968591","id":"PMC_25968591","title":"Cell toxicity of 2-hydroxyethyl methacrylate (HEMA): the role of oxidative stress.","date":"2015","source":"European journal of oral sciences","url":"https://pubmed.ncbi.nlm.nih.gov/25968591","citation_count":21,"is_preprint":false},{"pmid":"26315604","id":"PMC_26315604","title":"The role of previously untreated patient studies in understanding the development of FVIII inhibitors.","date":"2015","source":"Haemophilia : the official journal of the World Federation of Hemophilia","url":"https://pubmed.ncbi.nlm.nih.gov/26315604","citation_count":20,"is_preprint":false},{"pmid":"30550295","id":"PMC_30550295","title":"F8-IL10: A New Potential Antirheumatic Drug Evaluated by a PET-Guided Translational Approach.","date":"2018","source":"Molecular pharmaceutics","url":"https://pubmed.ncbi.nlm.nih.gov/30550295","citation_count":20,"is_preprint":false},{"pmid":"20626616","id":"PMC_20626616","title":"WAG-F8(m1Ycb) rats harboring a factor VIII gene mutation provide a new animal model for hemophilia A.","date":"2010","source":"Journal of thrombosis and haemostasis : JTH","url":"https://pubmed.ncbi.nlm.nih.gov/20626616","citation_count":20,"is_preprint":false},{"pmid":"18496863","id":"PMC_18496863","title":"HEMA down-regulates procollagen alpha1 type I in human gingival fibroblasts.","date":"2009","source":"Journal of biomedical materials research. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/18496863","citation_count":20,"is_preprint":false},{"pmid":"2034217","id":"PMC_2034217","title":"Cloning and nucleotide sequence of the hemA gene of Agrobacterium radiobacter.","date":"1991","source":"Molecular & general genetics : MGG","url":"https://pubmed.ncbi.nlm.nih.gov/2034217","citation_count":19,"is_preprint":false},{"pmid":"26483703","id":"PMC_26483703","title":"HEMA but not TEGDMA induces autophagy in human gingival fibroblasts.","date":"2015","source":"Frontiers in physiology","url":"https://pubmed.ncbi.nlm.nih.gov/26483703","citation_count":19,"is_preprint":false},{"pmid":"36107620","id":"PMC_36107620","title":"Immune tolerance against infused FVIII in hemophilia A is mediated by PD-L1+ Tregs.","date":"2022","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/36107620","citation_count":18,"is_preprint":false},{"pmid":"17610549","id":"PMC_17610549","title":"F8 gene mutation profile and ITT response in a cohort of Italian haemophilia A patients with inhibitors.","date":"2007","source":"Haemophilia : the official journal of the World Federation of Hemophilia","url":"https://pubmed.ncbi.nlm.nih.gov/17610549","citation_count":18,"is_preprint":false},{"pmid":"33245802","id":"PMC_33245802","title":"Mutation analysis in the F8 gene in 485 families with haemophilia A and prenatal diagnosis in China.","date":"2020","source":"Haemophilia : the official journal of the World Federation of Hemophilia","url":"https://pubmed.ncbi.nlm.nih.gov/33245802","citation_count":17,"is_preprint":false},{"pmid":"38452208","id":"PMC_38452208","title":"Vector integration and fate in the hemophilia dog liver multiple years after AAV-FVIII gene transfer.","date":"2024","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/38452208","citation_count":17,"is_preprint":false},{"pmid":"24296544","id":"PMC_24296544","title":"F8 genetic analysis strategies when standard approaches fail.","date":"2013","source":"Hamostaseologie","url":"https://pubmed.ncbi.nlm.nih.gov/24296544","citation_count":16,"is_preprint":false},{"pmid":"21833006","id":"PMC_21833006","title":"Integration-free and stable expression of FVIII using a human artificial chromosome.","date":"2011","source":"Journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/21833006","citation_count":16,"is_preprint":false},{"pmid":"18549909","id":"PMC_18549909","title":"The role of VWF in the immunogenicity of FVIII.","date":"2008","source":"Thrombosis research","url":"https://pubmed.ncbi.nlm.nih.gov/18549909","citation_count":15,"is_preprint":false},{"pmid":"33552050","id":"PMC_33552050","title":"Immune Responses to Plasma-Derived Versus Recombinant FVIII Products.","date":"2021","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/33552050","citation_count":15,"is_preprint":false},{"pmid":"34242570","id":"PMC_34242570","title":"Dissection of pleiotropic effects of variants in and adjacent to F8 exon 19 and rescue of mRNA splicing and protein function.","date":"2021","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/34242570","citation_count":15,"is_preprint":false},{"pmid":"26566286","id":"PMC_26566286","title":"Engineering less immunogenic and antigenic FVIII proteins.","date":"2015","source":"Cellular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/26566286","citation_count":14,"is_preprint":false},{"pmid":"37995690","id":"PMC_37995690","title":"Structural insights into the assembly and mechanism of mpox virus DNA polymerase complex F8-A22-E4-H5.","date":"2023","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/37995690","citation_count":14,"is_preprint":false},{"pmid":"30609275","id":"PMC_30609275","title":"The impact of GPIbα on platelet-targeted FVIII gene therapy in hemophilia A mice with pre-existing anti-FVIII immunity.","date":"2019","source":"Journal of thrombosis and haemostasis : JTH","url":"https://pubmed.ncbi.nlm.nih.gov/30609275","citation_count":14,"is_preprint":false},{"pmid":"12204009","id":"PMC_12204009","title":"Prevalence of small rearrangements in the factor VIII gene F8C among patients with severe hemophilia A.","date":"2002","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/12204009","citation_count":14,"is_preprint":false},{"pmid":"35950488","id":"PMC_35950488","title":"Heterogeneity and reciprocity of FVIII and VWF expression, and the response to shear stress in cultured human endothelial cells.","date":"2022","source":"Journal of thrombosis and haemostasis : JTH","url":"https://pubmed.ncbi.nlm.nih.gov/35950488","citation_count":13,"is_preprint":false},{"pmid":"25589203","id":"PMC_25589203","title":"Experimental self-etching HEMA-free adhesive systems: cytotoxicity and degree of conversion.","date":"2015","source":"Journal of materials science. Materials in medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25589203","citation_count":13,"is_preprint":false},{"pmid":"31089407","id":"PMC_31089407","title":"Protection against HEMA-Induced Mitochondrial Injury In Vitro by Nrf2 Activation.","date":"2019","source":"Oxidative medicine and cellular longevity","url":"https://pubmed.ncbi.nlm.nih.gov/31089407","citation_count":13,"is_preprint":false},{"pmid":"31315300","id":"PMC_31315300","title":"HEMA Effects on Autophagy Mechanism in Human Dental Pulp Stem Cells.","date":"2019","source":"Materials (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/31315300","citation_count":13,"is_preprint":false},{"pmid":"2842318","id":"PMC_2842318","title":"Cloning of the Rhodobacter capsulatus hemA gene.","date":"1988","source":"Journal of bacteriology","url":"https://pubmed.ncbi.nlm.nih.gov/2842318","citation_count":13,"is_preprint":false},{"pmid":"29296938","id":"PMC_29296938","title":"Accurate, simple, and inexpensive assays to diagnose F8 gene inversion mutations in hemophilia A patients and carriers.","date":"2016","source":"Blood advances","url":"https://pubmed.ncbi.nlm.nih.gov/29296938","citation_count":13,"is_preprint":false},{"pmid":"26435345","id":"PMC_26435345","title":"T cell response to FVIII.","date":"2015","source":"Cellular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/26435345","citation_count":12,"is_preprint":false},{"pmid":"35491676","id":"PMC_35491676","title":"Liver gene therapy with intein-mediated F8 trans-splicing corrects mouse haemophilia A.","date":"2022","source":"EMBO molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35491676","citation_count":12,"is_preprint":false},{"pmid":"32258210","id":"PMC_32258210","title":"Defining the Optimal FVIII Transgene for Placental Cell-Based Gene Therapy to Treat Hemophilia A.","date":"2020","source":"Molecular therapy. Methods & clinical development","url":"https://pubmed.ncbi.nlm.nih.gov/32258210","citation_count":12,"is_preprint":false},{"pmid":"36696179","id":"PMC_36696179","title":"Race, ethnicity, F8 variants, and inhibitor risk: analysis of the \"My Life Our Future\" hemophilia A database.","date":"2022","source":"Journal of thrombosis and haemostasis : JTH","url":"https://pubmed.ncbi.nlm.nih.gov/36696179","citation_count":12,"is_preprint":false},{"pmid":"26383047","id":"PMC_26383047","title":"Complexity and diversity of F8 genetic variations in the 1000 genomes.","date":"2015","source":"Journal of thrombosis and haemostasis : JTH","url":"https://pubmed.ncbi.nlm.nih.gov/26383047","citation_count":12,"is_preprint":false},{"pmid":"31756292","id":"PMC_31756292","title":"HEMA 3 Staining: A Simple Alternative for the Assessment of Myoblast Differentiation.","date":"2019","source":"Current protocols in stem cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/31756292","citation_count":12,"is_preprint":false},{"pmid":"28448958","id":"PMC_28448958","title":"Evaluation of F8-TNF-α in Models of Early and Progressive Metastatic Osteosarcoma.","date":"2017","source":"Translational oncology","url":"https://pubmed.ncbi.nlm.nih.gov/28448958","citation_count":12,"is_preprint":false},{"pmid":"28188892","id":"PMC_28188892","title":"The dental monomer hydroxyethyl methacrylate (HEMA) counteracts lipopolysaccharide-induced IL-1β release-Possible role of glutathione.","date":"2017","source":"Toxicology letters","url":"https://pubmed.ncbi.nlm.nih.gov/28188892","citation_count":12,"is_preprint":false},{"pmid":"18665854","id":"PMC_18665854","title":"Severe haemophilia A in a female resulting from an inherited gross deletion and a de novo codon deletion in the F8 gene.","date":"2008","source":"Haemophilia : the official journal of the World Federation of Hemophilia","url":"https://pubmed.ncbi.nlm.nih.gov/18665854","citation_count":12,"is_preprint":false},{"pmid":"10831786","id":"PMC_10831786","title":"Changes in cell phospholipid metabolism in vitro in the presence of HEMA and its degradation products.","date":"2000","source":"Dental materials : official publication of the Academy of Dental Materials","url":"https://pubmed.ncbi.nlm.nih.gov/10831786","citation_count":12,"is_preprint":false},{"pmid":"12203998","id":"PMC_12203998","title":"Identification of seven novel mutations of F8C by DHPLC.","date":"2002","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/12203998","citation_count":11,"is_preprint":false},{"pmid":"18459951","id":"PMC_18459951","title":"Mutational spectrum of F8 gene and prothrombotic gene variants in haemophilia A patients from Southern Italy.","date":"2008","source":"Haemophilia : the official journal of the World Federation of Hemophilia","url":"https://pubmed.ncbi.nlm.nih.gov/18459951","citation_count":11,"is_preprint":false},{"pmid":"36998673","id":"PMC_36998673","title":"Current Understanding of Inherited Modifiers of FVIII Pharmacokinetic Variation.","date":"2023","source":"Pharmacogenomics and personalized medicine","url":"https://pubmed.ncbi.nlm.nih.gov/36998673","citation_count":10,"is_preprint":false},{"pmid":"36490287","id":"PMC_36490287","title":"Separate roles of LMAN1 and MCFD2 in ER-to-Golgi trafficking of FV and FVIII.","date":"2023","source":"Blood advances","url":"https://pubmed.ncbi.nlm.nih.gov/36490287","citation_count":10,"is_preprint":false},{"pmid":"34662354","id":"PMC_34662354","title":"Role of ADAMTS13, VWF and F8 genes in deep vein thrombosis.","date":"2021","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/34662354","citation_count":10,"is_preprint":false},{"pmid":"14699993","id":"PMC_14699993","title":"Long distance PCR in detection of inversion mutations of F8C gene in hemophilia A patients.","date":"2003","source":"General physiology and biophysics","url":"https://pubmed.ncbi.nlm.nih.gov/14699993","citation_count":10,"is_preprint":false},{"pmid":"25503412","id":"PMC_25503412","title":"Characterisation and quantification of F8 transcripts of ten putative splice site mutations.","date":"2014","source":"Thrombosis and haemostasis","url":"https://pubmed.ncbi.nlm.nih.gov/25503412","citation_count":10,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":51753,"output_tokens":5480,"usd":0.11873,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":13416,"output_tokens":5294,"usd":0.099715,"stage2_stop_reason":"end_turn"},"total_usd":0.218445,"stage1_batch_id":"msgbatch_01AsR7g8dGTEiEw9U83bJeWn","stage2_batch_id":"msgbatch_01YV5ZyxtFNUZEjxRcpd9jzb","note":"batch pricing = 50% of standard"},"stage1_raw":"Looking through the abstracts, I need to identify papers about the canonical F8/FVIII protein (coagulation factor VIII) and extract mechanistic findings. I'll classify each paper:\n\n- Papers about HEMA (2-hydroxyethyl methacrylate, dental monomer): EXCLUDE (symbol collision)\n- Papers about bacterial hemA (glutamyl-tRNA reductase): EXCLUDE (symbol collision)\n- Papers about mpox virus F8 DNA polymerase: EXCLUDE (symbol collision)\n- Papers about F8-IL12, F8-TNF, F8-IL10 (antibody fragment targeting fibronectin EDA): EXCLUDE (different protein)\n- Papers about F8-actinomycin D: EXCLUDE (different molecule)\n- Papers about HEMA 3 staining: EXCLUDE\n- Papers about coagulation Factor VIII (F8/FVIII): INCLUDE\n\nNow extracting mechanistic discoveries from relevant papers:\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1987,\n      \"finding\": \"FVIII inhibitor epitopes map to either the 92-kDa polypeptide (and its 54-kDa/44-kDa thrombin fragments) or the 80-kDa polypeptide (and its 72-kDa thrombin fragment), establishing that inhibitory antibodies target distinct FVIII polypeptide domains. Inhibitors are of restricted polyclonal origin containing IgG-1 and IgG-4 subclasses, with different IgG subclasses showing differential reactivity to specific FVIII polypeptides.\",\n      \"method\": \"Immunoblotting of purified FVIII with inhibitor plasmas; affinity purification and quantitative radial immunodiffusion; monoclonal antibodies specific for IgG subclasses\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct immunoblotting of purified protein, multiple inhibitor plasmas tested, single lab with two orthogonal methods\",\n      \"pmids\": [\"2436689\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Combined deficiency of FV and FVIII (F5F8D) is caused by mutations in LMAN1 or MCFD2, which encode components of an ER-to-Golgi cargo receptor complex. MCFD2 is a calcium-dependent EF-hand domain protein that forms a heteromeric complex with LMAN1; missense mutations in MCFD2 EF-hand domains abolish interaction with LMAN1. The B domain of FVIII is implicated in mediating its interaction with the LMAN1-MCFD2 complex.\",\n      \"method\": \"Genetic mapping of F5F8D mutations; biochemical characterization of LMAN1-MCFD2 complex; mutational analysis of MCFD2 EF-hand domains\",\n      \"journal\": \"British journal of haematology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — review synthesizing multiple experimental studies identifying the cargo receptor complex; replicated across labs but this paper is a review\",\n      \"pmids\": [\"19183188\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"LMAN1-deficient mice show ~50% reduction in plasma FV and FVIII and platelet FV levels, confirming that the LMAN1-MCFD2 complex functions as an ER-to-Golgi cargo receptor for FV and FVIII. LMAN1 deficiency causes slight ER distension with accumulation of α1-antitrypsin and GRP78 in hepatocytes. LMAN1 deficiency had no effect on COPII-coated vesicle formation in vitro.\",\n      \"method\": \"LMAN1 knockout mouse analysis; plasma coagulation factor measurements; in vitro COPII vesicle formation assay; electron microscopy of hepatocytes; immunoblotting\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — genetic knockout model with direct measurement of cargo levels, in vitro vesicle assay, and ultrastructural analysis in a single rigorous study\",\n      \"pmids\": [\"21795745\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Regulated secretion of FVIII occurs only when there is endogenous synthesis of FVIII together with VWF in endothelial cells, demonstrating that co-synthesis with VWF is required for FVIII storage in regulated secretory pools (Weibel-Palade bodies) and stimulus-dependent release.\",\n      \"method\": \"DDAVP-stimulated release studies in endothelial cells; co-expression analysis of VWF and FVIII\",\n      \"journal\": \"Pediatric blood & cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional release assay with endogenous synthesis requirement demonstrated, single lab\",\n      \"pmids\": [\"16470522\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Stabilin-2 (encoded by STAB2) functions as a clearance and immunoregulatory receptor for the VWF-FVIII complex. Stabilin-2-expressing cells bind and internalize human VWF and FVIII in a VWF-dependent manner. Stabilin-2-deficient mice show prolonged human VWF-FVIII half-life. The stabilin-2 variant p.E2377K decreases stabilin-2 expression and impairs VWF endocytosis. Co-infusion of VWF-FVIII with stabilin-2 ligand hyaluronic acid attenuates the immune response to exogenous FVIII.\",\n      \"method\": \"Cell binding and internalization assays; stabilin-2 knockout mouse pharmacokinetic studies; heterologous expression of stabilin-2 variant; immunogenicity assays in STAB2-deficient mice\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (KO mouse PK, cell internalization, variant expression, immunogenicity) in a single rigorous study\",\n      \"pmids\": [\"30124466\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Mesenchymal stem cells (MSC) isolated from human lung, liver, brain, and bone marrow express FVIII mRNA and produce functional FVIII protein. In MSC, FVIII protein localizes to the perinuclear region rather than in granules, and functional FVIII is detectable in MSC supernatants and cell lysates.\",\n      \"method\": \"Quantitative RT-PCR; confocal immunofluorescence microscopy with FVIII-specific antibody; functional FVIII measurement by aPTT and chromogenic assays\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (RT-PCR, immunofluorescence, functional assay), single lab\",\n      \"pmids\": [\"23042590\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"VWF reduces the immunogenicity of FVIII by inhibiting uptake of FVIII by immature dendritic cells and inhibiting activation of FVIII-specific T cells in a dose-dependent manner. Recombinant VWF lacking the FVIII-binding domain did not inhibit T-cell activation, demonstrating that VWF must bind FVIII to exert its immunomodulatory effect.\",\n      \"method\": \"In vitro dendritic cell FVIII uptake assays; T-cell activation assays with VWF and VWF mutant lacking FVIII-binding domain\",\n      \"journal\": \"Thrombosis research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro functional assays with domain-deletion control, single lab review summarizing experimental findings\",\n      \"pmids\": [\"18549909\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"The F8 missense mutation c.6046C>T/p.R2016W in exon 19 exerts pleiotropic effects: it impairs both FVIII secretion (antigen ~11% of wild-type) and activity (~6% of wild-type) and decreases correct mRNA splicing to 70%. Antisense U7snRNA masking the mutated exon 19 region confirmed the presence of a splicing regulatory element. Additional clustered missense mutations (p.G2013R, p.E2018G, p.N2038S) also reduce exon inclusion, demonstrating that the amino acid and splicing codes overlap in this region.\",\n      \"method\": \"Lentiviral vector expression studies; minigene splicing assays; ectopic F8 mRNA analysis from patient samples; antisense U7snRNA rescue experiments; FVIII antigen and activity measurements\",\n      \"journal\": \"Haematologica\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — multiple orthogonal methods (patient mRNA, minigene, recombinant expression, antisense rescue) in a single study with mechanistic dissection\",\n      \"pmids\": [\"29170251\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Extensive characterization of 30 F8 exon 19 variants revealed pleiotropic effects on both mRNA splicing and protein biology. A single engineered U1snRNA rescued aberrant mRNA splicing of nine different F8 variants. A chaperone-like drug improved FVIII protein secretion for four missense variants impairing protein folding, establishing that protein folding and secretion are separable from splicing as pathogenic mechanisms.\",\n      \"method\": \"Recombinant expression assays; minigene splicing assays; in silico prediction algorithms; engineered U1snRNA rescue; chaperone drug treatment; FVIII antigen and activity measurement\",\n      \"journal\": \"American journal of human genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — multiple orthogonal methods across 30 variants with functional rescue experiments in a single rigorous study\",\n      \"pmids\": [\"34242570\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"A point mutation (Leu176Pro) in the A1 domain of rat FVIII causes hemophilia A by disrupting the tertiary structure of the FVIII molecule. The F8 gene has an autosomal location on chromosome 18 in rats (versus X-linked in mice and humans). Administration of human recombinant FVIII corrects the coagulation abnormality in affected rats.\",\n      \"method\": \"F8 cDNA sequencing to identify causative mutation; coagulation factor activity assays; FVIII replacement correction experiment\",\n      \"journal\": \"Journal of thrombosis and haemostasis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mutation identification with functional correction assay, single lab, animal model\",\n      \"pmids\": [\"20626616\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"The native F8 promoter drives FVIII expression predominantly in liver sinusoidal endothelial cells, with some expression in hematopoietic organs, as demonstrated by GFP reporter under pF8 in mice. Depletion of regulatory T cells (Tregs) in lentiviral-treated mice allowed formation of anti-FVIII antibodies, indicating that Tregs mediate immune tolerance to FVIII under pF8-driven gene therapy.\",\n      \"method\": \"Lentiviral vector with GFP reporter under native F8 promoter; in vivo GFP expression analysis; FVIII activity measurement; Treg depletion experiments in hemophilic mice\",\n      \"journal\": \"Blood advances\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct in vivo reporter assay for promoter activity, functional Treg depletion experiment, single lab\",\n      \"pmids\": [\"30862611\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"In human lymphatic endothelial cells (hLECs) where FVIII is significantly expressed, FVIII and VWF co-localize in Weibel-Palade bodies (WPBs) and are released together upon stimulation. A reciprocal relationship between FVIII and VWF expression levels exists across endothelial cell types. Exposure to laminar shear stress markedly reduces both FVIII and VWF expression in hLECs.\",\n      \"method\": \"Immunofluorescence microscopy; stimulated release assays; shear stress exposure; RNA and protein quantification across multiple endothelial cell types\",\n      \"journal\": \"Journal of thrombosis and haemostasis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct co-localization by immunofluorescence with stimulated release assay, multiple cell types compared, single lab\",\n      \"pmids\": [\"35950488\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"In ER-to-Golgi trafficking of FV and FVIII, MCFD2 is the primary cargo-binding component while LMAN1 serves mainly as a shuttling carrier of MCFD2. LMAN1 with mutations abolishing carbohydrate binding can still partially rescue FV/FVIII secretion, indicating N-glycan binding is not essential for FV/FVIII transport. Overexpression of either wild-type or mutant MCFD2 alone is sufficient to rescue FV/FVIII secretion in LMAN1-deficient cells.\",\n      \"method\": \"LMAN1- and MCFD2-deficient cell lines (HEK293T, HepG2, HCT116); FV/FVIII secretion assays; rescue experiments with LMAN1 carbohydrate-binding mutants and MCFD2 overexpression\",\n      \"journal\": \"Blood advances\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — multiple cell-type KO lines, mutagenesis of carbohydrate-binding domain, and rescue experiments with orthogonal approaches in a single study\",\n      \"pmids\": [\"36490287\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Immune tolerance to FVIII under non-hemophilic conditions is maintained by PD-L1-expressing regulatory T cells (Tregs) that ligate PD-1 on FVIII-specific B cells, causing B cell apoptosis. FVIII-deficient mice lack these Tregs and develop inhibitors. Repetitive FVIII injection in an ITI mouse model induces FVIII-specific PD-L1+ Tregs that re-engage removal of inhibitor-forming B cells. FVIII-specific Tregs upregulate PD-L1 in hemophilia patients after successful ITI.\",\n      \"method\": \"FVIII-deficient mouse model; ITI mouse model with repetitive FVIII injection; Treg characterization by flow cytometry; PD-1/PD-L1 blocking experiments; B cell apoptosis assays; human patient samples post-ITI\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — mechanistic dissection in mouse models and human patients, multiple orthogonal methods (flow cytometry, apoptosis assays, blocking experiments), replicated across species\",\n      \"pmids\": [\"36107620\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"MicroRNAs miR-374b-5p and miR-30c-5p suppress FVIII expression by targeting the 3' UTR of F8 mRNA. Overexpression of miR-374b or miR-30c decreased FVIII expression in cell lines that constitutively express FVIII, while an miR-30c inhibitor partially restored FVIII expression.\",\n      \"method\": \"miRNA sequencing from hemophilia A patients without F8 coding mutations; overexpression of specific miRNAs in FVIII-expressing cell lines; miRNA inhibitor rescue experiment; FVIII expression measurement\",\n      \"journal\": \"Transfusion\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct functional assay with miRNA overexpression and inhibitor rescue in FVIII-expressing cell lines, single lab, two miRNAs tested\",\n      \"pmids\": [\"31785023\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"A 23.4-kb tandem duplication of the proximal F8 gene (promoter, exon 1, and part of intron 1) causes twofold or greater upregulation of F8 mRNA and extremely elevated FVIII levels (>400%), resulting in severe thrombophilia. A 927-bp region within F8 intron 1 showed >45-fold increased reporter activity in endothelial cells in a luciferase assay, identifying it as a transcriptional enhancer element for F8.\",\n      \"method\": \"Genetic analysis of thrombophilic families; RNA quantification; luciferase reporter assay of intron 1 sequences in endothelial cells; chromatin accessibility (open chromatin signatures) analysis\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — luciferase reporter assay identifying functional enhancer, cosegregation in two families, RNA quantification; single lab\",\n      \"pmids\": [\"33275657\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"CRISPR/Cas9-mediated homology-directed repair can insert a functional B-domain-deleted FVIII gene at the FVIII locus in hemophilia A patient-derived iPSCs at high frequency (81.81%). Endothelial cells differentiated from gene-corrected iPSCs produce functionally active FVIII protein, demonstrating that the FVIII locus is a suitable site for integration and endothelial expression of corrected FVIII.\",\n      \"method\": \"CRISPR/Cas9 HDR gene targeting in patient iPSCs; iPSC differentiation to endothelial cells; FVIII functional activity assay\",\n      \"journal\": \"Experimental & molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genome editing with functional validation in differentiated cells, single lab\",\n      \"pmids\": [\"30996250\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"The FVIII peptide FVIII2194-2213 contains an immunodominant HLA-DRA*01-DRB1*01:01-restricted T-cell epitope. The core binding residues are F2196, M2199, A2201, and S2204. The substitution F2196A abrogates T-cell clone proliferation to the wild-type sequence. B-domain-deleted FVIII proteins with F2196K or M2199A substitutions show reduced immunogenicity while retaining procoagulant activity comparable to wild-type.\",\n      \"method\": \"Peptide-MHC class II binding assays; T-cell proliferation assays with Ala-substituted peptides; recombinant BDD-FVIII protein expression and functional activity measurement; T-cell clone stimulation with recombinant FVIII-C2 domain proteins\",\n      \"journal\": \"Blood advances\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — multiple orthogonal methods (MHC binding, T-cell clones, recombinant protein activity, natural processing validation) in a single rigorous study\",\n      \"pmids\": [\"29444872\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"FVIII (F8) is a coagulation cofactor synthesized predominantly in liver sinusoidal endothelial cells and co-secreted with VWF from Weibel-Palade bodies; its ER-to-Golgi transport requires the LMAN1-MCFD2 cargo receptor complex in which MCFD2 directly binds FV/FVIII cargo while LMAN1 serves as a shuttling carrier, VWF protects FVIII from proteolytic degradation in plasma and reduces its immunogenicity by blocking antigen-presenting cell uptake, stabilin-2 on endothelial cells mediates clearance of the VWF-FVIII complex, immune tolerance to therapeutic FVIII is maintained by PD-L1+ regulatory T cells that drive apoptosis of FVIII-specific B cells via PD-1 ligation, and F8 gene expression is regulated by an intronic enhancer element in intron 1 and fine-tuned post-transcriptionally by miRNAs targeting the 3' UTR.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"F8 encodes coagulation factor VIII (FVIII), a plasma procoagulant cofactor whose biology spans biosynthesis, intracellular trafficking, chaperoned secretion, plasma stabilization, clearance, and immune recognition [#2, #4]. Newly synthesized FVIII exits the ER via the LMAN1-MCFD2 cargo receptor complex, in which MCFD2 is the primary cargo-binding component and LMAN1 acts as a shuttling carrier; loss of this complex causes combined FV/FVIII deficiency and roughly halves plasma FVIII, while N-glycan binding by LMAN1 is dispensable for transport [#1, #2, #12]. FVIII is expressed predominantly in liver sinusoidal endothelial cells and in lymphatic endothelium, where co-synthesis with VWF directs it into Weibel-Palade bodies for stimulus-dependent regulated secretion [#10, #11, #3]. In plasma, VWF binding shields FVIII and limits its immunogenicity by blocking uptake by dendritic cells and downstream T-cell activation, and the VWF-FVIII complex is cleared through the endothelial scavenger receptor stabilin-2 [#6, #4]. Immune tolerance to FVIII is enforced by PD-L1+ regulatory T cells that ligate PD-1 on FVIII-specific B cells to drive their apoptosis; inhibitory antibodies that arise target distinct epitopes on the 92-kDa and 80-kDa FVIII polypeptides and an immunodominant HLA-DR-restricted T-cell epitope in the C2 region (residues 2194-2213) [#13, #0, #17]. F8 output is set transcriptionally by an intron 1 enhancer active in endothelial cells and post-transcriptionally by 3'UTR-targeting miRNAs, and pathogenic exon 19 variants act pleiotropically by simultaneously disrupting mRNA splicing and protein folding/secretion [#15, #14, #7, #8].\",\n  \"teleology\": [\n    {\n      \"year\": 1987,\n      \"claim\": \"Defined the molecular targets of pathogenic FVIII inhibitors, establishing that inhibitory antibodies recognize distinct FVIII polypeptide domains rather than a single site.\",\n      \"evidence\": \"Immunoblotting of purified FVIII against inhibitor plasmas with IgG subclass-specific monoclonals\",\n      \"pmids\": [\"2436689\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Did not map epitopes to specific residues or domains structurally\", \"Did not link epitope specificity to clinical inhibitor titer or persistence\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Showed that regulated, stimulus-dependent FVIII secretion requires endogenous co-synthesis with VWF, explaining how FVIII enters Weibel-Palade body storage pools.\",\n      \"evidence\": \"DDAVP-stimulated release and VWF/FVIII co-expression studies in endothelial cells\",\n      \"pmids\": [\"16470522\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Did not define the in vivo endothelial cell type responsible\", \"Trafficking determinants on FVIII directing WPB storage not mapped\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Established a mechanistic basis for VWF's immunoprotective effect by showing VWF must bind FVIII to block dendritic-cell uptake and T-cell activation.\",\n      \"evidence\": \"In vitro DC uptake and T-cell activation assays using VWF and a FVIII-binding-deficient VWF mutant\",\n      \"pmids\": [\"18549909\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vitro only; no in vivo immunogenicity confirmation\", \"Receptor mediating DC uptake of free FVIII not identified\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Identified the LMAN1-MCFD2 cargo receptor as the cause of combined FV/FVIII deficiency, defining a dedicated ER-to-Golgi export pathway for FVIII.\",\n      \"evidence\": \"Genetic mapping of F5F8D mutations and biochemical/mutational analysis of MCFD2 EF-hand domains (review)\",\n      \"pmids\": [\"19183188\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Review synthesis rather than primary data\", \"Precise FVIII B-domain determinants contacting the receptor not resolved\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Demonstrated in a rat model that a single A1-domain point mutation causes hemophilia A via tertiary structure disruption, correctable by FVIII replacement.\",\n      \"evidence\": \"F8 cDNA sequencing, coagulation activity assays, and recombinant FVIII correction in affected rats\",\n      \"pmids\": [\"20626616\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Structural disruption inferred, not directly visualized\", \"Rat F8 is autosomal, limiting direct comparison to human X-linked locus\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Provided in vivo genetic proof that LMAN1 functions as a FV/FVIII cargo receptor, with deficiency halving plasma factor levels without disrupting COPII vesicle formation.\",\n      \"evidence\": \"LMAN1-knockout mouse coagulation measurements, in vitro COPII assay, and hepatocyte EM\",\n      \"pmids\": [\"21795745\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Residual ~50% secretion implies an LMAN1-independent export route\", \"Did not separate LMAN1 from MCFD2 contributions\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Revealed that mesenchymal stem cells from multiple tissues can express and secrete functional FVIII, broadening the cellular sources of FVIII beyond endothelium.\",\n      \"evidence\": \"RT-PCR, confocal immunofluorescence, and aPTT/chromogenic functional FVIII assays in MSCs\",\n      \"pmids\": [\"23042590\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Physiological contribution of MSC-derived FVIII to plasma levels unknown\", \"Perinuclear (non-granular) localization mechanism not explained\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Showed that an exon 19 missense mutation is pleiotropic, simultaneously impairing splicing and protein secretion/activity, establishing overlap of the amino-acid and splicing codes in F8.\",\n      \"evidence\": \"Patient mRNA analysis, minigene splicing assays, lentiviral expression, and antisense U7snRNA rescue\",\n      \"pmids\": [\"29170251\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Single variant focus; generality across the gene not yet shown\", \"Therapeutic feasibility of antisense correction in vivo untested\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Identified stabilin-2 as a clearance and immunoregulatory receptor for the VWF-FVIII complex, linking plasma half-life to endothelial scavenging.\",\n      \"evidence\": \"Cell internalization assays, STAB2-knockout mouse pharmacokinetics, variant expression, and immunogenicity assays\",\n      \"pmids\": [\"30124466\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contribution of stabilin-2 versus other clearance receptors not quantified\", \"Mechanism linking clearance to reduced immunogenicity incompletely defined\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Mapped an immunodominant HLA-DR-restricted T-cell epitope in the C2 region and showed engineered substitutions reduce immunogenicity while preserving procoagulant activity.\",\n      \"evidence\": \"Peptide-MHC binding, T-cell clone proliferation with Ala-scan peptides, and recombinant BDD-FVIII activity assays\",\n      \"pmids\": [\"29444872\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Single epitope; full T-cell epitope repertoire not enumerated\", \"Reduced-immunogenicity variants not validated in vivo for tolerance\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Defined transcriptional control of F8 by localizing expression to liver sinusoidal endothelial cells under the native promoter and showed Tregs mediate tolerance to FVIII.\",\n      \"evidence\": \"GFP reporter under native F8 promoter in mice plus Treg depletion in hemophilic mice\",\n      \"pmids\": [\"30862611\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Treg subset identity left to later work\", \"Promoter elements driving LSEC specificity not dissected\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Established post-transcriptional regulation of F8 by identifying 3'UTR-targeting miRNAs that suppress FVIII expression.\",\n      \"evidence\": \"Patient miRNA sequencing plus miRNA overexpression and inhibitor rescue in FVIII-expressing cell lines\",\n      \"pmids\": [\"31785023\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Only two miRNAs tested; in vivo relevance to plasma FVIII unproven\", \"Endogenous regulatory contexts driving these miRNAs unknown\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Demonstrated that the FVIII locus itself is a viable site for HDR-based gene correction with functional endothelial FVIII output.\",\n      \"evidence\": \"CRISPR/Cas9 HDR insertion of B-domain-deleted FVIII in patient iPSCs and differentiation to FVIII-producing endothelial cells\",\n      \"pmids\": [\"30996250\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vivo engraftment and durable correction not tested\", \"Off-target and integration safety not assessed\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Identified an intron 1 transcriptional enhancer whose duplication drives F8 overexpression and thrombophilia, defining a cis-regulatory determinant of FVIII levels.\",\n      \"evidence\": \"Thrombophilic family genetics, RNA quantification, endothelial luciferase reporter assays, and chromatin accessibility analysis\",\n      \"pmids\": [\"33275657\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Trans-acting factors binding the enhancer not identified\", \"Cosegregation limited to two families\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Generalized the pleiotropy of exon 19 variants across 30 alleles and separated splicing defects from folding/secretion defects using distinct RNA- and protein-targeted rescues.\",\n      \"evidence\": \"Recombinant expression, minigene assays, engineered U1snRNA splicing rescue, and chaperone-drug secretion rescue across 30 variants\",\n      \"pmids\": [\"34242570\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Rescue approaches validated in cell models only\", \"Variant-specific mechanism assignment may not extend to other exons\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Extended the cellular map of FVIII to lymphatic endothelium, showing FVIII/VWF co-localization in WPBs, a reciprocal expression relationship, and shear-stress downregulation.\",\n      \"evidence\": \"Immunofluorescence, stimulated release assays, and shear-stress exposure across endothelial cell types\",\n      \"pmids\": [\"35950488\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Physiological contribution of lymphatic endothelium to plasma FVIII unclear\", \"Mechanism of reciprocal FVIII/VWF regulation undefined\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Defined a mechanism of natural and acquired tolerance to FVIII via PD-L1+ Tregs that drive PD-1-mediated apoptosis of FVIII-specific B cells, linking tolerance to inhibitor prevention and ITI success.\",\n      \"evidence\": \"FVIII-deficient and ITI mouse models, Treg flow cytometry, PD-1/PD-L1 blockade, B-cell apoptosis assays, and post-ITI human samples\",\n      \"pmids\": [\"36107620\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Antigen-specific Treg induction triggers incompletely defined\", \"Translation to predictive clinical biomarkers not established\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Resolved the division of labor within the FVIII export receptor, showing MCFD2 is the cargo-binding component while LMAN1 acts as its shuttling carrier and N-glycan binding is dispensable.\",\n      \"evidence\": \"LMAN1- and MCFD2-deficient HEK293T/HepG2/HCT116 lines with carbohydrate-binding mutant and MCFD2-overexpression rescue assays\",\n      \"pmids\": [\"36490287\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of MCFD2-FVIII cargo recognition not defined\", \"Identity of the residual LMAN1-independent secretion route unknown\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How transcriptional (intron 1 enhancer), post-transcriptional (miRNA), trafficking (LMAN1-MCFD2), and immune-tolerance (PD-L1+ Treg) layers are integrated to set physiological FVIII levels in vivo remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified in vivo model coupling FVIII output, clearance, and tolerance\", \"Trans-acting regulators of the F8 enhancer and miRNAs unidentified\", \"Structural mechanism of cargo recognition and inhibitor epitope architecture incomplete\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [2, 10]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0031410\", \"supporting_discovery_ids\": [3, 11]},\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [2, 12]},\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [4, 6]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-109582\", \"supporting_discovery_ids\": [2, 10]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [13, 17, 4]},\n      {\"term_id\": \"R-HSA-9609507\", \"supporting_discovery_ids\": [2, 12]}\n    ],\n    \"complexes\": [\n      \"Weibel-Palade body VWF-FVIII complex\"\n    ],\n    \"partners\": [\n      \"VWF\",\n      \"LMAN1\",\n      \"MCFD2\",\n      \"STAB2\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}